CAT-2000

CAT-2000 refers to a preclinical series of small‑molecule conjugates developed by Catabasis Pharmaceuticals using its SMART Linker technology to covalently link niacin (vitamin B3) with an omega‑3 fatty acid, such as eicosapentaenoic acid, into new chemical entities designed to modulate lipid metabolism and inflammation in serious lipid disorders.[1][7] Members of the CAT‑2000 series, including the lead compound CAT‑2003, target the sterol regulatory element‑binding protein (SREBP) pathway, a master regulator of genes controlling triglyceride and cholesterol synthesis, with the goal of lowering plasma triglycerides and LDL cholesterol and improving dyslipidemia and related metabolic diseases such as severe hypertriglyceridemia and nonalcoholic steatohepatitis.[1][6][7] The SMART Linker design allows intracellular activation of the conjugates, aiming to enhance efficacy over simple niacin plus omega‑3 combinations and potentially reduce niacin‑related tolerability issues such as flushing.[1]